



TYPE 2 DIABETES

Patient recruitment case study
with V601 activities

THE CHALLENGE

Type 2 diabetes (T2D) is a metabolic disorder where blood sugar control is characterized by high blood sugar, insulin resistance, and relative lack of insulin. T2D is often linked with conditions like obesity, high blood pressure, and elevated cholesterol. People with T2D are at higher risk for cardiovascular diseases (CVD), particularly those affecting the heart and brain. Obesity is a major risk factor for T2D, and research shows a strong connection between T2D and excess weight. The global obesity epidemic is leading to more cases of T2D and related issues like high cholesterol and high blood pressure, increasing the risk of complications affecting both small and large blood vessels. Treatments that lower blood sugar and promote weight loss could help improve T2D management, slow its progression, and reduce the risk of long-term complications.

THE TASK

Life Line Screening was tasked with recruiting our customers to participate in various trials for subjects with type 2 diabetes. The primary objective of these studies was to evaluate the safety and efficacy of an investigational medicine in people with type 2 diabetes.

Life Line Screening was responsible for engaging and educating potential participants on diabetes and cardiovascular health, performing V601 study activities—including abbreviated informed consent procedures and conducting laboratory assessments for participants with type 2 diabetes—and facilitating the transfer of participants to their designated clinical trial sites for Phase III of the trials.

RECRUITMENT

LIFE LINE SCREENING CONTACTED PARTICIPANTS
WHO MET THE FOLLOWING ELIGIBILITY CRITERIA:

PROTOCOL 1

- Confirmed Type 2 Diabetes diagnosis
- 18 years or over
- Have a BMI of 25 or higher
- Take at least 1 medicine to manage diabetes
- Have or at risk for heart disease

PROTOCOL 2

- Confirmed Type 2 Diabetes diagnosis
- 18 years or over
- Have a BMI of 25 or higher
- Take at least 1500mc of metformin each day

PROTOCOL 3

- Confirmed Type 2 Diabetes diagnosis
- 18 years or over
- Are not taking medicine to manage diabetes and using diet and exercise only to manage

PROTOCOL 4

- Confirmed Type 2 Diabetes diagnosis
- 18 years or over
- Take at least 1500mg of metformin daily
- Uncontrolled blood glucose levels using current medications

PROTOCOL 5

- Confirmed Type 2 Diabetes diagnosis
- 18 years or over
- Have a BMI of 23 or more
- Are treating diabetes with a combination or glargine, metformin, and SGLT2 inhibitors

OUR SOLUTION

Life Line Screening initiated outreach to identify specific cohorts through its dedicated Study Coordinator team. The specialist team engaged with potential participants who met preliminary eligibility criteria, providing education on diabetic health. Interested participants who met the inclusion/exclusion criteria completed an abbreviated informed consent with their designated Life Line Screening Study Coordinator. These participants were then scheduled for an appointment at a Life Line Screening mobile event, where a medical professional collected additional data, including height, weight, BMI, and HbA1c results. Following the completion of the mobile event, lab samples and source documents were sent by a dedicated courier to the designated laboratory and clinical trial site.

RESULTS

Life Line Screening completed 5 separate Type 2 diabetes protocols in 14 months. These activities included engaging with potential participants, educating them about the trial, scheduling a blood draw at a location near them, performing the HbA1c blood draw at a Life Line Screening mobile event, providing lab results to the participant, and transferring qualified participants to their designated enrollment site.

- **63 TOTAL COLLABORATING CLINICAL ENROLLMENT SITES**
- **30+ LIFE LINE SCREENING MOBILE TEAMS ENGAGED**
- **14 MONTHS OF OUTREACH**

DATA

90,000+ participants with Type 2 Diabetes located within 25 miles of enrollment centers

2,000 participants interested and completed qualifying questionnaire

298 consented participants

65 HbA1c V601 lab draws performed